A major breakthrough has emerged in the fight against metastatic pancreatic cancer. Daraxonrasib, marketed as Rasonque, has delivered impressive results in recent clinical trials, with data showing a confirmed objective response rate of 60.7%—meaning more than six in ten patients saw their tumors shrink or stop growing. The results, presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, follow the drug’s controversial fast-track approval by the U.S. Food and Drug Administration (FDA) in August 2026.
Promising Results in a Difficult Disease
Pancreatic cancer remains one of the deadliest cancers in the United States. According to the National Cancer Institute, it accounts for just over 3% of new cancer cases but causes over 8% of cancer deaths. The five-year survival rate for metastatic cases still languishes at just 3.4%. Against this grim backdrop, daraxonrasib’s performance is turning heads. In a cohort of 61 first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients tracked for a median of 18.3 months, 8.2% had a complete response to the drug, and nearly all saw their disease either shrink or stabilize.
The drug works by targeting a protein called RAS, which is abnormally active in the majority of pancreatic cancer patients. By “gluing” itself to this problematic protein, daraxonrasib effectively halts tumor growth. Revolution Medicines, the company behind Rasonque, is already running a global Phase 3 study to continue evaluating the drug’s potential, not just in pancreatic cancer but also in metastatic lung cancer.
Real-World Impact and Market Outlook
The potential impact of this drug is already being felt far beyond clinical trial reports. Former Nebraska Senator Ben Sasse, who has stage 4 metastatic pancreatic cancer, credits daraxonrasib for shrinking his tumor volume by 76%, calling it a “miracle drug” in multiple interviews. Revolution Medicines reported $198 million in sales in the drug’s first quarter on the market, and analysts at Truist Securities forecast that sales could hit $1.27 billion for the full year 2027, with the possibility of $2.3 billion annually by 2028 if approved for broader use.
While Cancer Research UK’s CEO Michelle Mitchell cautioned that survival rates for pancreatic cancer remain very low and more trials are needed before a wider rollout, the new data is raising hopes in a field where progress has been painfully slow.